Pearce S H
Department of Medicine, University of Newcastle upon Tyne, UK.
QJM. 1998 Jan;91(1):5-12. doi: 10.1093/qjmed/91.1.5.
Advances in the molecular genetics of inherited renal tubulopathies have allowed some insight into the normal mechanisms of tubular cation and anion reabsorption. It is now possible to view Bartter's syndrome, Gitelman's syndrome and pseudohypoaldosteronism type 1 as having genetic abnormalities which produce tubular defects that are similar to those induced by the pharmacological actions of loop diuretics, thiazide diuretics or potassium-sparing diuretics, respectively. Although these rare monogenic disorders with dramatic phenotypes seem to have little relevance to everyday clinical practice, it is possible that subtle abnormalities of the regulation of the ENaCs may play a role in low-renin forms of 'essential' hypertension. Similarly, subtle abnormalities in the function of the electroneutral sodium-(potassium)-chloride cotransporters (NKCC2 and NCCT) and the renal CLC-type chloride channels (CLC5) may be major determinants of urinary calcium excretion with roles in the pathogenesis of 'idiopathic' hypercalciuria and osteoporosis. Because of the intricate and diverse molecular mechanisms by which tubular reabsorption of water and solutes takes place in each different nephron segment, it is likely that other renal channels and transporters will be implicated in the pathogenesis of further monogenic disorders, and that these will allow additional insights into tubular functioning. Recent studies have demonstrated that in addition to abnormalities in the NKCC2 and ROMK1 genes, mutations at a third genetic locus can also cause Bartter's syndrome. Linkage studies, followed by mutational analyses have found deletions and point mutations in the gene encoding one of the TAL-specific chloride channels, CLCKB, in 17 Bartter's families. This chloride channel is similar in structure to CLC5, and is located on the long arm of chromosome 1. Importantly, there appears to be a phenotypic difference between subjects with Bartter's syndrome due to CLCKB abnormalities and those with NKCC2 or ROMK1 mutations. Despite the fact that all of these Bartter's patients had significant hypercalciuria, nephrocalcinosis was not found in any of the 17 subjects with CLCKB mutations, compared to 19 of 20 patients with NKCC2 or ROMK1 mutations. These findings have also demonstrated a key role for CLCKB as a major basolateral chloride channel involved in mTAL sodium and chloride reabsorption (Figure 2).
遗传性肾小管疾病分子遗传学的进展使我们对肾小管阳离子和阴离子重吸收的正常机制有了一定的了解。现在可以认为,巴特综合征、吉特曼综合征和1型假性醛固酮减少症分别具有遗传异常,这些异常会导致肾小管缺陷,分别类似于袢利尿剂、噻嗪类利尿剂或保钾利尿剂的药理作用所诱发的缺陷。尽管这些具有显著表型的罕见单基因疾病似乎与日常临床实践关系不大,但上皮钠通道(ENaC)调节的细微异常可能在低肾素型“原发性”高血压中起作用。同样,电中性钠-(钾)-氯共转运体(NKCC2和NCCT)以及肾CLC型氯通道(CLC5)功能的细微异常可能是尿钙排泄的主要决定因素,在“特发性”高钙尿症和骨质疏松症的发病机制中起作用。由于每个不同肾单位段中肾小管对水和溶质的重吸收存在复杂多样的分子机制,其他肾通道和转运体很可能参与更多单基因疾病的发病机制,并且这将使我们对肾小管功能有更多的了解。最近的研究表明,除了NKCC2和ROMK1基因异常外,第三个基因位点的突变也可导致巴特综合征。连锁研究随后进行的突变分析发现,在17个巴特综合征家族中,编码一种厚壁升支粗段特异性氯通道CLCKB的基因存在缺失和点突变。这种氯通道在结构上与CLC5相似,位于1号染色体长臂上。重要的是,由于CLCKB异常导致的巴特综合征患者与NKCC2或ROMK1突变患者之间似乎存在表型差异。尽管所有这些巴特综合征患者都有明显的高钙尿症,但在17例CLCKB突变患者中均未发现肾钙质沉着,而20例NKCC2或ROMK1突变患者中有19例出现肾钙质沉着。这些发现还证明了CLCKB作为参与髓袢升支粗段钠和氯重吸收的主要基底外侧氯通道的关键作用(图2)。